Roche purchases shares in tender offer for 89bio, Inc

Core Viewpoint - Roche has successfully completed its tender offer for 89bio, acquiring approximately 60.49% of its outstanding shares at a price of $14.50 per share, plus potential milestone payments of up to $6.00 per share through a contingent value right (CVR) [1][2]. Company Overview - 89bio is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardiometabolic diseases, currently in Phase 3 trials for its lead candidate, pegozafermin, targeting metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) [4]. - Roche, founded in 1896, is the world's largest biotechnology company and a leader in in-vitro diagnostics, committed to scientific excellence and personalized healthcare [5]. Acquisition Details - Roche's subsidiary, Bluefin Merger Subsidiary, Inc., will merge with 89bio without requiring a vote from 89bio's stockholders, converting all remaining shares into the same consideration as the tender offer [3]. - The tender offer expired on October 29, 2025, and was not extended, with a total of approximately 94,113,710 shares tendered [2][3].